Abstract: Renal Cell Carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and has a worldwide mortality. However, mortality rates have barely improved over the last 20 years. Novel biomarkers and biomarkers are thus urgently required for this cancer. The inventors have devised a strategy to produce mouse cancer cell lines of progressively enhanced aggressiveness and specialization. The mouse renal cancer cell line RENCA was serially passaged in vivo using multiple implantation strategies designed to replicate different aspects of primary tumour growth and metastasis. Transcriptomic and epigenomic data has been acquired for the derived cell lines and primary analyses have been performed. The inventors then selected plurality of genes with no reported role in RCC which were upregulated in their specialized cell lines, and checked their relevance in patient data and clinical samples.

Abstract: The invention relates to methods and compositions for selecting a cancer treatment in a subject suffering from cancer. The inventors have identified a 2-genes signature that determines the presence or absence of the primary cilium in relationship to the presence of VDAC1-AC. The inventors provide a new way to classify patients suffering from cancer and propose potential therapeutic targets linked to metabolism and immunotherapy. In particular, the invention relates to methods for selecting a cancer treatment in a subject suffering from cancer, wherein said method comprises the step of determining, in a biological sample (e.g. tissue biopsy) obtained from said subject, the expression level of GLI family zinc finger 1 (GLI1) and intraflagellar transport 20 (IFT20) and concluding the cancer treatment of said subject.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formulae (I) and (II), and a pharmaceutical composition comprising such compound for use for treating a cancer, particularly a cancer overexpressing CXCR1 and CXCR2 receptors, such as medulloblastoma, head and neck and kidney cancer. The invention further relates to such compounds for use for treating macular degeneration.

Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a cancer, in particular renal cell carcinoma (RCC) to sunitinib, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.

Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor, in particular renal cell carcinoma (RCC) to a cancer treatment, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.